Plasma-derived therapies (PDTs) are critical, life-transforming treatments that can only be produced from human plasma. PDTs are used to treat a range of rare and complex conditions like, immunodeficiencies, peripheral nerve disorders and bleeding disorders among others. However, global patient need far outpaces available supply. This is largely due to increasing and earlier diagnosis and an inadequate supply of donated plasma due to policies and regulations that lag behind scientific progress. Furthermore, unequal access to vital plasma therapies, especially in low- and middle-income countries, leaves some patients with inadequate treatment and aggravates global health inequity.

This initiative aims to find local solutions to the global issue of sustainable plasma supply used to manufacture critical lifesaving plasma-derived therapies for patients who rely on them globally by achieving the following objectives:
• Establish multi-stakeholder working groups in pilot countries to work towards and identify a shared vision and pathway towards strengthening local health systems to meet patient need for PDTs
• Establish a public knowledge platform based on up-to-date scientific evidence and best practices to become the go-to reference for experts, decision makers and the public
• Deliver targeted training, awareness and education among the community of experts and decision-makers
• Raise global awareness among international stakeholder community on the initiative
• Define pathway for scaling up the project and expanding the partnership